Abstract

Objective:To determine if adding etanercept (ETN) to methotrexate (MTX) or MTX to ETN for 52 weeks in rheumatoid arthritis (RA) patients with moderate disease activity provides higher efficacy.Methods:All patients (n...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0320 Patient-assessed disease activity score (PDAS) corresponds to standard disease statuses and response criteria defined by disease activity score 28 (DAS28) and clinical disease activity index (CDAI)
M.-H.A Leung ... D Farewell
Annals of the Rheumatic Diseases | VOL. 71
M.-H.A Leung, et. al.M.-H.A Leung ... D Farewell
01 Jun 2013
Anti-atherosclerotic effects of etanercept in Rheumatoid Arthritis Patients
Hiroaki Taguchi ... Yutaka Okano
Japanese Journal of Clinical Immunology | VOL. 35
Hiroaki Taguchi, et. al.Hiroaki Taguchi ... Yutaka Okano
01 Jan 2012
AB1176 Disease Control Among Serbian Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Findings from Daily Practice
S Stojanovic ... M Icevic
Annals of the Rheumatic Diseases | VOL. 74
S Stojanovic, et. al.S Stojanovic ... M Icevic
01 Jun 2015
Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Atsushi Kawakami ... Shohei Kuroda
Medicine | VOL. 101
Atsushi Kawakami, et. al.Atsushi Kawakami ... Shohei Kuroda
14 Jan 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers